APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China.
Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...
February 26, 2020
No Comments
APEIRON Announces Collaboration with Lead Discovery Center GmbH

Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach. Press release Presseaussendung

September 20, 2018
No Comments
APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor. Press release Presseaussendung  

July 17, 2018
No Comments
APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor.

APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA. Presseaussendung Press Release

July 2, 2018
No Comments
EIB Blog featuring APEIRON („Three Ways to Treat Cancer”)

The European Investment Bank blog is featuring APEIRON Biologics AG in following article: http://www.eib.org/stories/new-cancer-treatments

June 25, 2018
No Comments
APEIRON Biologics AG to present clinical data at the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO).

APEIRON Biologics AG today announced it would present data on two of its key programs in three poster presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held on June 1-5, 2018, in Chicago, IL. Presseaussendung Press Release

May 30, 2018
No Comments
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance With Sanofi

APEIRON Biologics AG and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. Press release Presseaussendung

January 8, 2018
No Comments
APEIRON to Present at the Biotech Showcase™ Annual Conference 2018

APEIRON Biologics AG today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing. Press release Presseaussendung

January 5, 2018
No Comments